In this section
@article{McKibben:2018:10.1038/s41533-018-0096-4,
author = {McKibben, S and Bush, A and Thomas, M and Griffiths, C},
doi = {10.1038/s41533-018-0096-4},
journal = {npj Primary Care Respiratory Medicine},
title = {"Tossing a coin:" defining the excessive use of short-acting beta(2)-agonists in asthma-the views of general practitioners and asthma experts in primary and secondary care},
url = {http://dx.doi.org/10.1038/s41533-018-0096-4},
volume = {28},
year = {2018}
}
TY - JOUR
AB - The National Review of Asthma Deaths (NRAD) identified high prescribing of short–acting beta2-agonists (SABAs) as a key factor in over 40% of deaths. We interviewed asthma experts from both a hospital background (n = 5) and a primary care background (n = 8), and general practitioners delivering asthma care (n = 8), to identify how SABA use is defined and perceived. We identified disparity in how acceptable SABA use is defined, ranging from 0.5 (100 doses/year) to 12 SABA inhalers (2400 doses/year), and complacency in the perception that over-use did not represent a marker for risk of asthma death. Despite current evidence, these findings suggest clinicians of various backgrounds are complacent about excessive SABA use.
AU - McKibben,S
AU - Bush,A
AU - Thomas,M
AU - Griffiths,C
DO - 10.1038/s41533-018-0096-4
PY - 2018///
SN - 2055-1010
TI - "Tossing a coin:" defining the excessive use of short-acting beta(2)-agonists in asthma-the views of general practitioners and asthma experts in primary and secondary care
T2 - npj Primary Care Respiratory Medicine
UR - http://dx.doi.org/10.1038/s41533-018-0096-4
UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439206800001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR - http://hdl.handle.net/10044/1/62008
VL - 28
ER -
--tojpeg_1473680102479_x4.jpg)